In contrast, oncogenic pathways such as MYC targets V2, E2F targets, and the G2M checkpoint were markedly downregulated (p < 0.01), indicating potential tumor-suppressive effects at the transcriptional level (Fig. 1b–c). The gene discussed is MYC; the disease is neoplasm.